| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6265ee57772eb27b36a59ebdb06829cc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f257f76fba798d6123c85a558b464fde
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d2f1f734483004c1a9bbead4362dc866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_da2600e73ae69807f7d58921de23bee1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7da5c8e8c3e8261efe7e698c7198681b |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5254
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-20061 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-215
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-215 |
| filingDate |
2006-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b34a60160f500ab326bc3dbb1a358b8a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a3f4a797a36d5921db76f8efcc51e46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6f6faab6a1298adbba78a7f3fe4f807
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_eccf3f944495196f4de4e1dc17ab6004 |
| publicationDate |
2006-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006136448-A2 |
| titleOfInvention |
Attenuated sars and use as a vaccine |
| abstract |
The present invention relates to nucleic acids encoding attenuated SARS-CoV viruses which are capable of producing a maximum viral titer in cell culture that is reduced at least by a factor of 2 when compared to the maximum viral titer of wild-type SARS-CoV virus in the same cell culture. According to a further aspect of the present invention, the nucleic acids encoding an attenuated SARS-CoV virus, are obtainable by a method comprising steps, wherein the genome of a SARS-CoV virus is modified by amending the sequence of the gene encoding the SARS-CoV E protein so that the nucleic acid cannot express a functional E protein. The present invention further relates to the viruses encoded by these nucleic acids as well as the medical use of the nucleic acids and of the viruses. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022120369-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022103870-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10485861-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022066823-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021194603-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2014153087-A1 |
| priorityDate |
2005-06-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |